 Shore Capital has reiterated its buy stance on pharma giant AstraZeneca following data on its late-stage breast cancer drugs presented at a San Antonio conference, AstraZenecas projects have the potential to reshape treatment outcomes and redefine the standard of care within breast cancer, said the broker. Shore reiterated a price target of 127 by the end of 2023, up from almost 114 currently. 